CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / NOVO Nordisk A S (NVO) / cagrilintide
Forward catalyst · NVO

cagrilintide

Sponsor NOVO Nordisk A S · listed as NVO

READOUT Phase 3 Confidence: medium Source: clinicaltrials

cagrilintide is a clinical-stage drug asset sponsored by NOVO Nordisk A S, listed as NVO. CSA tracks 4 forward catalysts for it — the nearest is a readout expected Mar 1, 2027 (day precision, medium confidence), tied to trial NCT07011667. The asset is in Phase 3 and currently active not recruiting, studied in Obesity. It appears across 9 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-03-01
As disclosedMar 1, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT07011667
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNovo Nordisk A/S
Listed asNVO
Condition(s)Obesity

All tracked catalysts for cagrilintide

DateEventConfidenceTrial
2027-03-01READOUTmediumNCT07011667
2027-05-11READOUTmediumNCT07220642
2027-05-12READOUTmediumNCT07220759
2027-09-01READOUTmediumNCT05669755
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More NVO catalysts